nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2013-17-1-11-19nefr-531Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEКАРДИО-ВАСКУЛЯРНО-РЕНАЛЬНЫЕ СВЯЗИ В КАРДИОРЕНАЛЬНОМ КОНТИНУУМЕCARDIOVASCULAR AND RENAL LINKS ALONG THE CARDIORENAL CONTINUUMГарсиа-ДонаиреЖ. А.García-DonaireJ. A.

Jos´e A. Garc´ıa-Donaire 

Avenida C´ordoba s/n, 28041 Madrid

Avenida C´ordoba s/n, 28041 Madrid

docdonaire@terra.esРуилопеЛ. М.RuilopeL. M.

Avenida C´ordoba s/n, 28041 Madrid

ВоронковаЕ. В.VoronkovaE. B.

Перевод с английского

Translation from English

Hypertension Unit, Hospital 12 de OctubreИспанияHypertension Unit, Hospital 12 de OctubreSpain2013100120131711119Copyright © Гарсиа-Донаире Ж.А., Руилопе Л.М., Воронкова Е.В., 20132013Гарсиа-Донаире Ж.А., Руилопе Л.М., Воронкова Е.В.García-Donaire J.A., Ruilope L.M., Voronkova E.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/531

Кардиоренальный синдром включает в себя широко известные взаимоотношения между функцией почек и болезнями сердечно-сосудистой системы. Во всем мире как в развитых, так и в развивающихся странах, у большого числа пациентов имеется дисфункция сердца и почек различной степени выраженности. Причем, при поражении одной из систем оказывается заинтересованной и вторая. Подобная взаимосвязь отображает патогенез клинического состояния, именуемого кардиоренальный синдром. Для болезней почек и сердечно-сосудистой системы характерны схожие этиологические факторы риска. Причиной подавляющего большинства сосудистых событий служит прогрессирующий атеросклероз. Более того, сердечно-сосудистые события редко встречаются у пациентов при отсутствии лежащих в их основе болезней, напротив, в типичных случаях они являются результатом финальной стадии патологического процесса, который, при отсутствии контроля указанных факторов, приводит к прогрессирующему повреждению сосудов, включая поражение жизненно важных органов, в частности, почек и сердца. Хроническая болезнь почек является новейшим фактором риска, который, присоединяясь на определенном этапе, усиливает как повреждение сосудов, так и сердца.

The cardiorenal syndrome includes the widely known relationship between kidney function and cardiovascular disease. A large number of patients have various degrees of heart and kidney dysfunction worldwide, both in developed and developing countries. Disorders affecting one of themmostly involve the other. Such interactions represent the pathogenesis for a clinical condition called cardiorenal syndrome. Renal and cardiovascular disease shares similar etiologic risk factors. The majority of vascular events arecaused by accelerated atherosclerosis. Moreover, cardiovascular events rarely occur in patients without underlying disease; rather, they typically take place as the final stage of a pathophysiological process that results in progressive vascular damage, including vital organ damage, specifically the kidney and the heart if these factors are uncontrolled. Chronic kidney disease is a novel risk factor included at this stage that accelerates both vascular and cardiac damage.

кардиоренальный континуумкардиоренальный синдром(ы)кардиоренальные взаимоотношенияcardiorenal continuumcardiorenal syndromecardiorenal relationshipsReferencesHall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens 1996; 10(10): 633–639Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens 1996; 10(10): 633–639Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. NEJM 1999; 341(8): 577–585Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. NEJM 1999; 341(8): 577–585Brown JR, Cochran RP, Leavitt BJ, et al. Multivariable prediction of renal insufficiency developing after cardiac surgery. Circulation 2007; 116(11): I139–I143Brown JR, Cochran RP, Leavitt BJ, et al. Multivariable prediction of renal insufficiency developing after cardiac surgery. Circulation 2007; 116(11): I139–I143Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. JASN 2005; 16(2): 489–495Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. JASN 2005; 16(2): 489–495Gruberg L, Weissman NJ, Waksman R, et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 2002; 89(1): 54–57Gruberg L, Weissman NJ, Waksman R, et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol 2002; 89(1): 54–57Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006; 114(25): 2871–2891Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006; 114(25): 2871–2891Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31(6): 703–711Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31(6): 703–711Ruilope LM, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk—implications for management: a consensus statement from the European Society of Hypertension. Blood Press 2007; 16(2): 72–79Ruilope LM, Kjeldsen SE, de la Sierra A, et al. The kidney and cardiovascular risk—implications for management: a consensus statement from the European Society of Hypertension. Blood Press 2007; 16(2): 72–79Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001; 38(6): 1372–1375Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001; 38(6): 1372–1375Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. NEJM 2004; 351(19): 1941–1951Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. NEJM 2004; 351(19): 1941–1951Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24(2): 403–408Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24(2): 403–408Sjølie AK, Bilous R, Chaturvedi N, et al. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6(1): 25–32Sjølie AK, Bilous R, Chaturvedi N, et al. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6(1): 25–32Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–2031Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–2031Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–886Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–886Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353(9153): 611–616Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353(9153): 611–616Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(9227): 359–365Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(9227): 359–365The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997The ONTARGET/TRANSCEND investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-I-Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61The ONTARGET/TRANSCEND investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-I-Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66(1): 51–83.Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66(1): 51–83.Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. NEJM 2000; 342: 145–153Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. NEJM 2000; 342: 145–153Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008; 358(15): 1547–1559Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008; 358(15): 1547–1559Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. NEJM 2006; 354(16): 1685–1697Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. NEJM 2006; 354(16): 1685–1697Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA) Lancet 2003; 361: 1149–1158Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA) Lancet 2003; 361: 1149–1158Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEJM 2008; 359(23): 2417–2428Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEJM 2008; 359(23): 2417–2428Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–2572Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–2572Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2007; 25(6): 1105–1187Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2007; 25(6): 1105–1187Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034–2047Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034–2047Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44(1): 84–93Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44(1): 84–93Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100Moe S, Drueke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31–41Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31–41Ruilope LM, Zanchetti A, Julius S et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007; 25(7): 1473–1479Ruilope LM, Zanchetti A, Julius S et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007; 25(7): 1473–1479Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145(4): 237–246Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145(4): 237–246Parving HH. Initiation and progression of diabetic nephropathy. NEJM 1996; 335(22): 1682–1683Parving HH. Initiation and progression of diabetic nephropathy. NEJM 1996; 335(22): 1682–1683Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314(7083): 783–788Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314(7083): 783–788Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20(3): 353–355Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20(3): 353–355Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106(14): 1777–1782Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106(14): 1777–1782Ärnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the framingham heart study. Circulation 2005; 112(7): 969–975Ärnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the framingham heart study. Circulation 2005; 112(7): 969–975Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300(6720): 297–300Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300(6720): 297–300Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286(4): 421–426Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286(4): 421–426Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997; 80(2): 164–169Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997; 80(2): 164–169Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 2006; 21(9): 2366–2374Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 2006; 21(9): 2366–2374Segura J, Ruilope LM. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fundam Clin Pharmacol 2005; 19(4): 429–437Segura J, Ruilope LM. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fundam Clin Pharmacol 2005; 19(4): 429–437Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167(11): 1130–1136Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167(11): 1130–1136Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994; 23(1): 3–9Ruilope LM, Lahera V, Rodicio JL, Romero JC. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994; 23(1): 3–9Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16(11): 3403–3410Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16(11): 3403–3410Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36(2): 51–62Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36(2): 51–62Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 2002; 4(5): 332–336Segura J, Campo C, Ruilope LM. How relevant and frequent is the presence of mild renal insufficiency in essential hypertension? J Clin Hypertens (Greenwich) 2002; 4(5): 332–336Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15(5): 1307–1315Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15(5): 1307–1315Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15(6): 1616–1622Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15(6): 1616–1622Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13(3): S165–S168Ruilope LM. The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13(3): S165–S168Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116(1): 85–97Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116(1): 85–97Tucker B, Fabbian F, Giles M, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplan. 1997; 12(4): 724–728Tucker B, Fabbian F, Giles M, et al. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplan. 1997; 12(4): 724–728Wachtell K, Olsen MH, Dahlöf B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20(3): 405–412Wachtell K, Olsen MH, Dahlöf B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20(3): 405–412Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110(1): 32–35Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110(1): 32–35Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM 2001; 345(12): 861–869Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM 2001; 345(12): 861–869Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEJM 2001; 345(12): 851–860Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEJM 2001; 345(12): 851–860Heart Outcomes Prevention Evaluation Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259Heart Outcomes Prevention Evaluation Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEJM 2001; 345(12): 870–878Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEJM 2001; 345(12): 870–878Feringa HHH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007; 18(6): 1872–1879Feringa HHH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007; 18(6): 1872–1879Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244–I36Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244–I36Ruilope LM, Alcazar JM, Hernandez E et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; [suppl 45]: S171–S173Ruilope LM, Alcazar JM, Hernandez E et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; [suppl 45]: S171–S173

The authors declare that there are no conflicts of interest present.